- Report
- March 2024
- 194 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- July 2022
- 203 Pages
Global
From €6913EUR$7,150USD£5,938GBP
- Report
- January 2023
- 124 Pages
From €2030EUR$2,100USD£1,744GBP
€2900EUR$3,000USD£2,491GBP
- Report
- January 2023
- 134 Pages
Middle East, Africa
From €2030EUR$2,100USD£1,744GBP
€2900EUR$3,000USD£2,491GBP
- Report
- January 2023
- 160 Pages
Asia Pacific
From €2030EUR$2,100USD£1,744GBP
€2900EUR$3,000USD£2,491GBP
- Report
- January 2023
- 146 Pages
North America
From €2030EUR$2,100USD£1,744GBP
€2900EUR$3,000USD£2,491GBP
- Report
- January 2023
- 153 Pages
Europe
From €2030EUR$2,100USD£1,744GBP
€2900EUR$3,000USD£2,491GBP
- Report
- October 2022
- 209 Pages
Global
From €3079EUR$3,185USD£2,645GBP
€4399EUR$4,550USD£3,778GBP
- Report
- March 2024
- 109 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- March 2024
- 114 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Drug Pipelines
- March 2021
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,201GBP
Oxybutynin is a drug used to treat symptoms of overactive bladder, a urological disorder. It is an anticholinergic drug, meaning it works by blocking the action of a certain neurotransmitter in the body. Oxybutynin is available in both oral and topical forms, and is often prescribed in combination with other medications. Common side effects include dry mouth, constipation, and blurred vision.
Oxybutynin is one of the most commonly prescribed drugs for urological disorders, and is widely available in both generic and brand name forms. It is often used as a first-line treatment for overactive bladder, and is also used to treat urinary incontinence.
Companies in the Oxybutynin market include Pfizer, Mylan, Teva Pharmaceuticals, and Actavis. Show Less Read more